Sign In
Buy PULM
$1.29
-0.0300 (-2.27%)
At Close: Jun 03, 2026
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
08:05am, Friday, 10'th May 2024
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Ph
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
09:05am, Thursday, 28'th Mar 2024
2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a signif
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
09:05am, Thursday, 09'th Nov 2023
Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in H2 20
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
09:05am, Tuesday, 19'th Sep 2023
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine BEDFORD,
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
11:16am, Monday, 11'th Sep 2023
Pulmatrix, Inc. (PULM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could me
Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazole Pulmatrix is currently enrolli
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
09:05am, Thursday, 10'th Aug 2023
Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and topline data anticipated in Q3
LEXINGTON, Mass. , July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to ad
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
09:05am, Wednesday, 24'th May 2023
Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXINGTON, Mass. , May 24, 2023 /PRNewswire/ -- Pulmat
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
09:05am, Monday, 23'rd Jan 2023
LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
10:35pm, Monday, 09'th May 2022 Zacks Investment Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
12:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today?
02:31pm, Tuesday, 01'st Mar 2022 InvestorPlace
As Pulmatrix executes a reverse stock split, shares of the tiny pharmaceutical company appear to be defying gravity.
Which U.S. Companies Are Cutting Ties With Russia? See Latest List.
10:59am, Tuesday, 01'st Mar 2022
U.S. companies are cutting ties with Russia due to the war with Ukraine and we're going over which ones traders need to know about. The post Which U.S. Companies Are Cutting Ties With Russia?
